Alexandra Albertsson Lindblad

affiliated with the university
More filtering options
  1. 2019
  2. 2018
  3. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Eskelund, C. W., Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Pedersen, L. B., Geisler, C. H., Mats Jerkeman & Grønbæk, K., 2018, In : Haematologica. 103, 11, p. e541-e543

    Research output: Contribution to journalLetter

  4. Mantle cell lymphoma strategies in primary treatment

    Alexandra Albertsson Lindblad, 2018, Lund: Lund University: Faculty of Medicine. 130 p.

    Research output: ThesisDoctoral Thesis (compilation)

  5. 2016
  6. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

    Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M-L., Sundström, C., Mats Ehinger, Geisler, C. & Mats Jerkeman, 2016 Jun 27, In : Blood. 128, 14, p. 1814-1820

    Research output: Contribution to journalArticle

  7. 2014
  8. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

    Abrahamsson, A., Alexandra Albertsson Lindblad, Brown, P. N., Baumgartner-Wennerholm, S., Pedersen, L. M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H. & Mats Jerkeman, 2014, In : Blood. 124, 8, p. 1288-1295

    Research output: Contribution to journalArticle